Abstract
BackgroundOvarian cancer (OC) is a leading cause of cancer-related death in women, and thus an accurate diagnosis of the predisposition and its early detection is necessary. The aims of this study were to determine whether serum exosomal microRNA-34a (miR-34a) in ovarian cancer could be used as a potential biomarker.MethodsExosomes from OC patients’ serum were collected, and exosomal miRNAs were extracted. The relative expression of miR-34a was calculated from 58 OC samples by quantitative real-time polymerase chain reaction.ResultsSerum exosomal miR-34a levels were significantly increased in early-stage OC patients compared with advanced-stage patients. Its levels were significantly lower in patients with lymph node metastasis than in those with no lymph node metastasis. Furthermore, its levels in the recurrence group were significantly lower than those in the recurrence-free group.ConclusionsSerum exosomal miR-34a could be a potential biomarker for improving the diagnostic efficiency of OC.
Highlights
Ovarian cancer (OC) is a leading cause of cancer-related death in women, and an accurate diagnosis of the predisposition and its early detection is necessary
These results suggest the successful extraction of serum exosomes
Association of serum exosomal miR-34a level and cancer recurrence We investigated whether circulating levels of exosomal miR-34a were related to recurrence in OC patients
Summary
Ovarian cancer (OC) is a leading cause of cancer-related death in women, and an accurate diagnosis of the predisposition and its early detection is necessary. The aims of this study were to determine whether serum exosomal microRNA-34a (miR-34a) in ovarian cancer could be used as a potential biomarker. The standard therapy for ovarian cancer is cytoreductive surgery and postoperative adjuvant chemotherapy with platinum-based compounds. MicroRNAs (miRNAs) consist of 18–25 nucleotides and are highly conserved. It is well-known that mature miRNAs regulate gene expression by binding to complementary nucleotide sequences in 3′ untranslated regions (UTRs) of target messenger RNAs (mRNAs) [3].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.